Halozyme Therapeutics HALO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's EBITDA?
- Halozyme Therapeutics (HALO) reported EBITDA of $188.74M in Q1 2026.
- How has Halozyme Therapeutics's EBITDA changed year-over-year?
- Halozyme Therapeutics's EBITDA increased by 30.9% year-over-year, from $144.22M to $188.74M.
- What is the long-term trend for Halozyme Therapeutics's EBITDA?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's EBITDA has grown at a 26.3% compound annual growth rate (CAGR), from $278.91M to $561.77M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.